SC 13G 1 d885744dsc13g.htm SC 13G SC 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. __)

 

 

VIR BIOTECHNOLOGY, INC.

(Name of Issuer)

 

 

Common Stock

(Title of Class of Securities)

92764N 102

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ☐

Rule 13d-1(b)

 

  ☐

Rule 13d-1(c)

 

  ☒

Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 92764N 102    13G    Page 2 of 5 Pages

 

  1  

Names of Reporting Persons

 

George A. Scangos

  2  

Check the Appropriate Box if a Member of a Group

(a)  ☐ (b)  ☐

 

  3  

SEC Use Only

 

  4  

Citizenship or Place of Organization

 

United States of America

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting   
Person  

With:  

    5       

Sole Voting Power

 

4,804,844 Shares (1)

   6   

Shared Voting Power

 

2,144,135 Shares (2)

   7   

Sole Dispositive Power

 

4,804,844 Shares (1)

   8   

Shared Dispositive Power

 

2,144,135 Shares (2)

  9  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

6,948,979 Shares

10  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ☐

 

11  

Percent of Class Represented by Amount in Row (9)

 

6.3% (3)

12  

Type of Reporting Person

 

IN

 

(1)

Includes 328,091 shares of common stock issuable within 60 days of December 31, 2019 upon the exercise of stock options held by the Reporting Person.

(2)

Represents shares held in the name of the George A. Scangos 2018 Annuity Trust dated August 30, 2018, of which the Reporting Person and his spouse are Trustees.

(3)

This percentage is calculated based on 109,678,822 shares of common stock outstanding as of November 15, 2019, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on November 19, 2019.

 

CUSIP No. 92764N 102    13G    Page 3 of 5 Pages

 

Item

1(a).        

   

Name of Issuer:

Vir Biotechnology, Inc.

Item

1(b).

   

Address of Issuer’s Principal Executive Offices:

499 Illinois Street, Suite 500

San Francisco, CA 94158

Item

2(a).

   

Names of Persons Filing:

George A. Scangos

Item

2(b).

   

Address of Principal Business Office, or, if none, Residence:

499 Illinois Street, Suite 500

San Francisco, CA 94158

Item

2(c).

   

Citizenship:

United States of America

Item

2(d).

   

Title of Class of Securities:

Common Stock

Item

2(e).

   

CUSIP No.:

92764N 102

  

 

Item 3.

Not Applicable.

 

Item 4.

Ownership

The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Person is provided as of December 31, 2019:

 

(a)

Amount beneficially owned

See Row 9 of cover page.

 

(b)

Percent of Class:

See Row 11 of cover page.

 

(c)

Number of shares as to which such person has:

 

  (i)

Sole power to vote or to direct the vote: See Row 5 of cover page.

 

  (ii)

Shared power to vote or to direct the vote: See Row 6 of cover page.

 

  (iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page.

 

  (iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page.

 

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ☐

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable

 

CUSIP No. 92764N 102    13G    Page 4 of 5 Pages

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

 

Item 8.

Identification and Classification of Members of the Group

Not applicable

 

Item 9.

Notice of Dissolution of Group

Not applicable

 

CUSIP No. 92764N 102    13G    Page 5 of 5 Pages

 

Item 10.

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2020

 

/s/ George A. Scangos
George A. Scangos